Fed. Circ. Questions If Safer OxyContin Profits Came From IP

By Dani Kass · October 7, 2024, 9:39 PM EDT

An attorney for Purdue Pharma didn't seem to find much purchase at the Federal Circuit on Monday as he argued that the company's patents for abuse-deterrent OxyContin weren't obvious, claiming other...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

Purdue Pharma L.P. v. Accord Healthcare, Inc.

Case Number

23-1953

Court

Appellate - Federal Circuit

Nature of Suit

835 Patent - (ANDA) (Fed. Qst.)

Date Filed

May 30, 2023

Featured Stories

Meet The Attorneys Helping Hearthside Through Ch. 11 No Photo Available

Hilary Russ

When it filed for bankruptcy late last month in Texas, under the shadow of child labor investigations, the parent company of Hearthsid... (more story)

Purdue, FTX Top Biggest Bankruptcy Cases, Trends Of 2024 No Photo Available

Alex Wittenberg

The U.S. Supreme Court's decision to throw out nonconsensual third-party releases in opioid maker Purdue Pharma's Chapter 11 reverbera... (more story)

Meet The Attys Behind EV Co. Ideanomics' Ch. 11 No Photo Available

Yun Park

A team of attorneys from Foley & Lardner LLP and Ashby & Geddes PA is representing New York-based electric-vehicle technology company ... (more story)